Year All2026202520242023202220212020201920182017201620152014201320122011201020092008 Date Title Additional Formats 27 May 2026 BioLineRx Reports First Quarter 2026 Financial Results and Provides Corporate Update PDF Version 22 May 2026 BioLineRx and Hemispherian AS Highlight New Data on GLIX1 at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting PDF Version 20 May 2026 BioLineRx to Report First Quarter 2026 Results on May 27, 2026 PDF Version 19 May 2026 BioLineRx and Hemispherian Announce New GLIX1 Data Demonstrating Potent Anti-Tumor Effect in Glioblastoma (GBM) Across Multiple In-Vivo Studies, Including a Temozolomide (TMZ)-Resistant Model with Patient-Derived Xenografts PDF Version 28 Apr 2026 BioLineRx and Hemispherian Announce First Patient Dosed in Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM) PDF Version 26 Mar 2026 BioLineRx Announces Initiation of Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM) PDF Version 23 Mar 2026 BioLineRx Reports 2025 Financial Results and Provides Corporate Update PDF Version 16 Mar 2026 BioLineRx to Report 2025 Annual Results on March 23, 2026 PDF Version
